NAD+ for Longevity and Energy: What Science Says?

What Is NAD+ and Why Does It Matter?

Nicotinamide adenine dinucleotide, better known as NAD+, is a coenzyme found throughout the body. Cells use it to transfer electrons during metabolic reactions that help convert carbohydrates, fats, and proteins into usable energy.

NAD+ is especially important inside the mitochondria. These structures generate much of the adenosine triphosphate, or ATP, used to power muscle contraction, nerve signaling, repair, and other cellular activities.

NAD+ also acts as a required substrate for several groups of enzymes, including:

• Sirtuins, which help regulate metabolism, stress responses, inflammation, and mitochondrial function.
• PARP enzymes, which participate in DNA damage detection and repair.
• CD38 and related enzymes, which influence calcium signaling and immune activity.

NAD+ availability appears to decline in several tissues during aging, although the degree of decline varies by tissue, health status, and measurement method. Reduced production, inflammation, DNA damage, and increased activity of NAD-consuming enzymes may all contribute.

This creates an attractive theory: if lower NAD+ contributes to declining cellular function, restoring NAD+ might support healthier aging.

The important word is might.

What Dr. David Sinclair’s NAD+ Research Found

Dr. David Sinclair’s laboratory has spent decades studying sirtuins, mitochondrial function, epigenetic regulation, and NAD+ metabolism. His lab helped establish the connection between NAD+ availability, sirtuin activity, energy metabolism, and aging biology.

The Sinclair Lab continues to investigate compounds that raise NAD+ and whether those compounds can influence aging and age-related disease.

One of the lab’s most influential studies examined communication between the cell nucleus and mitochondria in aging mice. The researchers found that declining NAD+ contributed to a “pseudohypoxic” state in which mitochondrial function became disrupted. Increasing NAD+ with NMN improved parts of this signaling problem in the animals.

In another Sinclair-associated study, NMN improved blood flow and exercise endurance in older mice by restoring an NAD+-dependent signaling network in blood vessels.

These findings helped establish NAD+ restoration as a serious area of aging research. They also generated excitement around NMN and other NAD+ precursors.

However, these were primarily animal and mechanistic studies. A result in an aged mouse does not establish that the same compound will extend lifespan, prevent disease, or restore youthful energy in a human.

Sinclair’s work provides a scientific hypothesis—not a confirmed human anti-aging protocol.

Can NAD+ Actually Improve Energy?

NAD+ is necessary for energy metabolism, but taking an NAD+ booster is not the same as taking a stimulant.

Caffeine can make someone feel more alert within a relatively predictable period. NAD+ precursors are intended to alter cellular metabolism over time. Even when supplementation raises blood NAD+ metabolites, the person may not feel an immediate or dramatic change.

Some human studies have produced encouraging results.

A six-week study of 48 recreational runners tested 300, 600, or 1,200 milligrams of NMN per day during frequent exercise training. The medium- and high-dose groups experienced improvements in certain ventilatory-threshold measurements. However, the study did not find improvements in VO2 max, oxygen pulse, peak power, or several other performance measures.

Other studies have been less positive. In older men with diabetes and impaired physical performance, 250 milligrams of NMN daily for 24 weeks did not significantly improve grip strength or walking speed.

A 2025 systematic review and meta-analysis concluded that the available evidence did not support NMN or NR for preserving muscle mass or overall muscle function in adults over 60.

The most accurate interpretation is that NAD+ precursors may affect specific aspects of metabolism or performance in certain populations, but they are not proven energy-enhancing treatments for everyone.

Someone experiencing persistent fatigue should not assume that low NAD+ is the cause. Poor sleep, inadequate calorie intake, iron deficiency, thyroid disorders, medication effects, depression, overtraining, and numerous medical conditions can produce similar symptoms.

NAD+ for Longevity: Promising Biology, Limited Proof

The case for NAD+ for longevity rests on several observations:

1. NAD+ participates in mitochondrial energy production and cellular repair.
2. NAD+ metabolism changes during aging.
3. Restoring NAD+ improves multiple aspects of health in several animal models.
4. Oral NR and NMN can raise NAD-related metabolites in humans.

What is missing is evidence that these changes extend human lifespan.

No completed clinical trial has shown that NAD+, NR, or NMN allows healthy people to live longer. Human trials are generally small, run for several weeks or months, and measure biomarkers rather than lifespan.

Some findings are still meaningful.

In a 10-week randomized trial, 250 milligrams of NMN per day improved skeletal-muscle insulin sensitivity and insulin-signaling activity in postmenopausal women with prediabetes who were overweight or obese. The intervention did not produce universal metabolic improvement, but it showed that NMN can affect a biologically relevant pathway in humans.

In another randomized trial, 500 milligrams of NR twice daily for six weeks increased NAD-related metabolites in healthy middle-aged and older adults. Researchers also identified preliminary cardiovascular signals worth studying further, but the trial was not designed to demonstrate longer life or disease prevention.

A 12-week trial using 250 milligrams of NMN daily reported higher blood NAD+ levels, better sleep-quality measurements, and maintenance of walking speed in older adults. Those results are encouraging, but they still require confirmation in larger independent trials.

Raising a biomarker is not automatically the same as improving healthspan. The critical question is whether the increase produces meaningful, durable benefits with acceptable long-term risk.

NAD+, NMN and NR: What Is the Difference?

The names are often used interchangeably in marketing, but they are not the same compound.

NAD+ is the final coenzyme used by cells. It is commonly offered through IV infusions because intact NAD+ has limited direct oral and cellular uptake.

NMN is an NAD+ precursor. The body can use NMN and its metabolites to support NAD+ synthesis through salvage pathways.

NR is another vitamin B3-related precursor. It is converted into NMN and then into NAD+ inside the body.

Most controlled human studies have used oral NR or NMN rather than direct oral NAD+. Oral precursors are also less invasive and generally more practical than receiving repeated infusions.

Dosage and Frequency Used in Human Research

There is currently no universally accepted medical dosage for NAD+ longevity treatment. The following amounts describe research protocols, not personalized recommendations.

Most oral studies use once-daily dosing. Some divide the daily amount, but researchers have not established that divided dosing is superior.

There is also no strong evidence that NMN or NR must be taken in the morning, at night, on an empty stomach, or in scheduled cycles.

For IV NAD+, there is no evidence-based weekly, monthly, or quarterly maintenance frequency. Clinics may advertise loading phases followed by maintenance infusions, but those schedules have not been validated through long-term randomized longevity trials.

Are NAD+ Infusions Better Than Oral Supplements?

IV therapy places a compound directly into the bloodstream, but greater exposure does not automatically mean greater long-term benefit.

A 2019 pilot study administered 750 milligrams of NAD+ over six hours. It provided useful information about how infused NAD+ was metabolized, but it did not demonstrate improvements in energy, cognition, disease risk, or longevity.

A 2026 retrospective study compared four consecutive daily infusions of 500 milligrams of NAD+ with IV NR. People receiving NAD+ reported moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during treatment. Average NAD+ infusion time was 97 minutes, compared with 37 minutes for NR. Symptoms resolved when the infusions ended.

That study was small, retrospective, conducted in a commercial setting, and funded by the clinic involved. Most authors were clinic employees, and the NR product was donated. It therefore provides preliminary tolerability data rather than proof that either infusion improves longevity.

IV treatment also introduces risks unrelated to NAD+ itself, including infection, vein irritation, dosing errors, and complications from improperly prepared products.

At present, oral precursors have more human research behind them and are significantly easier to study over longer periods. That does not prove they produce meaningful anti-aging benefits.

What About Subcutaneous NAD+ Injections?

Subcutaneous, or SubQ, NAD+ is injected into the fatty tissue beneath the skin rather than directly into a muscle or vein. Clinics often present it as a more convenient alternative to IV infusions because it can be administered in a small injection and may be prescribed for home use.

The major limitation is evidence: subcutaneous NAD+ has not been proven to improve energy, slow aging, enhance exercise performance, or extend lifespan.

What Has Actually Been Studied?

One small registered pilot trial compared NAD+, nicotinamide riboside, and placebo through subcutaneous, intramuscular, and intravenous-push administration.

The subcutaneous NAD+ arm used:

• 100 milligrams of NAD+
• Diluted in 2 milliliters of bacteriostatic water
• Administered once daily for three consecutive days

Only six participants received subcutaneous NAD+ in this pilot. The study primarily examined absorption, injection discomfort, vital signs, laboratory measurements, and short-term tolerability—not improvements in energy or longevity.

A 2026 preprint combining preliminary results from two injection studies reported no unexpected safety signals attributable to the injections. However, participants experienced varying degrees of discomfort, and the research has not yet established clinical benefits. The report was a preprint rather than a peer-reviewed efficacy trial.

Therefore, 100 milligrams daily for three days should be described as an experimental research dose—not a validated NAD+ loading protocol.

Do Not Confuse Injectable NAD+ With Injectable NR

A separate study is examining subcutaneous nicotinamide riboside, or NR, which is a precursor the body can use to produce NAD+. It is not the same as injecting NAD+ itself.

That study uses:

• 50 or 100 milligrams of NR subcutaneously.
• Once daily for three consecutive days.
• Followed by the same dose three times weekly—Monday, Wednesday, and Friday—through approximately Day 100.

The study is designed primarily to evaluate safety, tolerability, and changes in blood NAD+ measurements. It does not establish that this frequency improves longevity or daily energy.

This distinction matters because wellness marketing frequently refers to both products simply as “NAD shots.”

Is There an Established SubQ NAD+ Dosage?

There is currently no medically established dose or frequency for subcutaneous NAD+ for energy, wellness, or longevity.

Commercial clinics advertise widely different schedules, including:

• 20 to 50 milligrams per injection.
• 50 to 100 milligrams one to three times weekly.
• Approximately 30 milligrams daily.
• Five-day-per-week schedules.
• Short loading phases followed by weekly maintenance.

These are commercial or prescriber-created protocols, not schedules validated through randomized clinical-outcome trials. The variation itself demonstrates the absence of a scientific dosing consensus.

A research dose tells us what investigators are testing. It does not tell us what dose an individual should use indefinitely.

Is SubQ NAD+ Better Than IM or IV NAD+?

That has not been established.

Subcutaneous administration is generally expected to produce more gradual absorption than an IV injection, but researchers have not yet shown that this creates better tissue delivery, longer-lasting NAD+ elevation, fewer systemic symptoms, or superior health outcomes.

Researchers still need to determine:

• How much intact NAD+ reaches circulation.
• How much is broken down before cellular uptake.
• Whether injected NAD+ raises NAD+ inside muscle, brain, or other tissues.
• How long any increase lasts.
• Whether SubQ injections outperform oral NR or NMN.
• Whether any biochemical change produces noticeable energy or longevity benefits.

The registered route-comparison study is intended to answer some absorption and tolerability questions, but it is too small and too short to establish anti-aging effectiveness.

Possible Side Effects and Injection Risks

Subcutaneous injections may produce:

• Burning or stinging.
• Redness and swelling.
• Bruising.
• Persistent lumps or irritation.
• Bleeding.
• Infection or abscess formation.
• Reactions to the drug, preservative, or diluent.

Repeated injections also require appropriate site rotation and sterile handling.

Product quality may be a more serious concern than the NAD+ molecule itself. The FDA has received reports of severe chills, shaking, vomiting, and fatigue following compounded NAD+ injections, with some patients requiring medical treatment. The agency stated that these reactions were consistent with excessive endotoxin contamination and warned compounders not to use food-grade ingredients when producing sterile injectable drugs.

A compounded product is not automatically unsafe, but its sterility, active ingredient quality, concentration, diluent, storage, and beyond-use date are critical.

Dr. David Sinclair’s Work Does Not Establish a SubQ Protocol

Dr. David Sinclair’s work supports studying NAD+ metabolism, sirtuins, NMN, mitochondrial function, and age-related NAD+ decline.

It does not establish a human subcutaneous NAD+ dose, loading phase, maintenance schedule, or longevity protocol.

Much of the foundational Sinclair research used cellular models, mice, or NAD+ precursors rather than repeated subcutaneous injections of intact NAD+ in humans. His research should not be cited as proof that commercial SubQ injection programs improve energy or extend life.

Bottom Line on SubQ NAD+

Subcutaneous NAD+ is more convenient than a lengthy IV infusion and may be easier to use repeatedly than an intramuscular injection. However, convenience is currently its clearest advantage.

Direct human evidence is limited to a very small pilot using 100 milligrams daily for three days. That research examined short-term absorption and tolerability—not longevity, fatigue, cognitive performance, or disease prevention.

There is no validated maintenance frequency, and commercial schedules ranging from daily injections to occasional weekly doses should not be presented as evidence-based protocols.

What About Safety?

Short-term oral NMN and NR have generally been well tolerated in clinical studies. Doses vary widely, and most trials have lasted only a few weeks or months.

Reported effects across NAD-related studies have included headache, fatigue, muscle discomfort, sleep changes, gastrointestinal symptoms, and other mild complaints. Serious treatment-related events have been uncommon in short studies, but long-term safety remains uncertain.

Support NAD+ Metabolism Without Starting a Supplement

Supplements are not the only way to influence NAD+ metabolism.

Exercise appears to support the body’s NAD+ recycling machinery. In one human study, 12 weeks of aerobic or resistance training increased proteins involved in the NAD+ salvage pathway in skeletal muscle, including the rate-limiting enzyme NAMPT.

That does not mean exercise raises NAD+ in every tissue or produces the same effect as supplementation. It does show that the body’s NAD+ system responds to lifestyle.

A longevity strategy should therefore prioritize:

• Regular aerobic and resistance exercise.
• Adequate sleep and circadian consistency.
• Sufficient calories, protein, vitamins, and minerals.
• Management of insulin resistance and cardiovascular risk.
• Avoidance of chronic sleep deprivation and excessive alcohol intake.

An NAD+ product should be viewed as an experimental addition—not a substitute for these foundations.